Delayed Prescribing Supporting Resource: Prescribing instructions for SystmOne and Emis Users(922 KB)
Date added: 9th Oct 2025
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| TIRZEPATIDE (Mounjaro®) (UPDATED) | Red | Management of overweight and obesity |
September 2025: Tirzepatide for weight loss and obesity is currently restricted to prescribing within specialist weight management services. For further details, please refer to the LLR Position Statement Tirzepatide (Mounjaro®) for Obesity Management. Until an implementation plan is established, Tirzepatide should not be prescribed in primary care for this indication. |
| APOMORPHINE | Orange | Parkinson's disease |
|
| AZATHIOPRINE (UPDATED) | Orange | Dermatological disease | |
| AZATHIOPRINE (UPDATED) | Orange | Paediatric Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) |
|
| AZATHIOPRINE | Orange | Rheumatological disease | |
| AZATHIOPRINE | Orange | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) & Autoimmune Hepatitis | |
| AZATHIOPRINE | Orange | Autoimmune neurological disorders |
Please see SCA for individual indications |
| COLISTIN (Colomycin ® and Promixin®) (UPDATED) | Yellow | Bronchiectasis |
Please see guide for more information. Must be prescribed by brand as the brands are not interchangeable. May 2025: Promixin is being discontinued, to use remaining stock for existing patients. Patients prescribed Promixin in primary care should be referred back to specialist team for review. |
| MEMANTINE | Yellow | Alzheimer's disease |
In line with NICE NG 97
|
| MEMANTINE (NEW) | Green | Alzheimer's Disease |
GPs may initiate memantine in patients already established on treatment in memory services and stabilised on a cholinesterase inhibitor In line with NICE NG 97 |
| MERCAPTOPURINE (UPDATED) | Orange | Paediatric Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) | |
| METHOTREXATE Oral (UPDATED) | Orange | Rheumatological disease |
Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied. |
| METHOTREXATE Oral (UPDATED) | Orange | Dermatological disease |
Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied |
| METHOTREXATE Oral (UPDATED) | Orange | Crohn's Disease |
Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied |
| MYCOPHENOLATE MOFETIL (UPDATED) | Orange | Autoimmune conditions |
Please see shared care agreement for individual indications |
| ZURANOLONE (Zurzuvae®) (NEW) | Do not prescribe |
Other Updates on this Website
Recent documents from LLR APC and TAS
Delayed Prescribing Supporting Resource: Video Guide for Emis Users
Date added: 9th Oct 2025
Delayed Prescribing Supporting Resource: Video Guide for SystmOne Users
Date added: 9th Oct 2025
Implementing Back-up (delayed) Antibiotic Prescribing(247 KB)
Date added: 9th Oct 2025
Haloperidol 0.5mg Tablets Review Process(569 KB)
Date added: 8th Oct 2025
LLR APC newsletter – August / September 2025(330 KB) - LMSG/LLR APC newsletters
Date added: 18th Sep 2025
Methotrexate Rheumatology Request Form(876 KB)
Date added: 17th Sep 2025
Methotrexate Dermatology Request Form(852 KB)
Date added: 17th Sep 2025
Methotrexate Adult Gastroenterology Request Form(852 KB)
Date added: 17th Sep 2025
Paediatric Mercaptopurine Shared Care Agreement(426 KB)
Date added: 17th Sep 2025
LLR Position Statement: Tirzepatide (Mounjaro®) for Obesity Management(114 KB)
Date added: 11th Sep 2025
Azathioprine (Peadiatric Gastroenterology)(425 KB)
Version 3.0 uploaded December 2024
Date added: 6th Dec 2024
Methotrexate Rheumatology/Dermatology/Gastroenterology SCA(591 KB) - Shared care agreement
Version 1 Uploaded December 2022/January 2023
Date added: 29th Dec 2022
Ciclosporin Dermatology Shared Care Agreement(638 KB) - Shared care agreement
Version 1 Uploaded December 2022/January 2023
Version 3 uploaded 05/06/2025
Date added: 29th Dec 2022
Leflunomide Shared Care Request Form(585 KB) - Shared care agreement
Date added: 4th May 2016
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more